Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: A review of natural history and treatment

JAMA Neurology

Volumn 71, Issue 9, 2014, Pages 1181-1185

  Yaghi, Shadi ^a   Eisenberger, Andrew ^a   Willey, Joshua Z ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; AMINOCAPROIC ACID; FIBRINOGEN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULATION; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CRANIOTOMY; CRYOPRECIPITATE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FIBRINOGEN BLOOD LEVEL; HEMATOMA; HEMATOMA EXPANSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; OUTCOME ASSESSMENT; PEER REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; FIBRINOLYTIC THERAPY; STROKE;

BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84907507278     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1210     Document Type: Review

References (27)

1. Jauch EC, Saver JL, Adams HP Jr, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1588.
3. Wahlgren N, Ahmed N, Dávalos A, et al SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282.
4. Goldstein JN, Marrero M, Masrur S, et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol. 2010;67(8):965-969.
5. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352(9136):1245-1251.
6. Matrat A, De Mazancourt P, Derex L, et al. Characterization of a severe hypofibrinogenemia induced by alteplase in two patients thrombolysed for stroke. Thromb Res. 2013;131(1):e45-e48. doi:10.1016/j.thromres.2012.11.009.
7. Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43(9):2293-2299.
8. Gumbinger C, Gruschka P, Böttinger M, et al. Improved prediction of poor outcome after thrombolysis using conservative definitions of symptomatic hemorrhage. Stroke. 2012;43(1):240-242.
9. Trouillas P1, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke. 2004;35(6):1323-1328.
10. Hamann GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction-possible mechanisms. Thromb Haemost. 1999;82(suppl 1):92-94.
11. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brainmicrovessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65(1):1-9.
12. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption inmice after focal cerebral ischemia and reperfusion. Brain Res. 1999;842(1):92-100.
13. Peters O, Back T, Lindauer U, et al. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1998;18(2):196-205.
14. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31(12):3034-3040.
15. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;67(7):1272-1274.
16. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001;115(1):145-149.
17. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6(4):622-631.
18. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: ameta-analysis. Thromb Haemost. 2011;106(3):429-438.
19. Thompson GH, Florentino-Pineda I, Armstrong DG, Poe-Kochert C. Fibrinogen levels following Amicar in surgery for idiopathic scoliosis. Spine (Phila Pa 1976). 2007;32(3):368-372.
20. French KF, White J, Hoesch RE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care. 2012;17(1):107-111.
21. Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and networkmeta-analysis of randomised and observational studies. BMJ. 2012;345:e5798. doi:10.1136/bmj.e5798.
22. Danés AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang. 2008;94(3):221-226.
23. Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood. 1992;79(1):91-98.
24. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood. 1986;68(1):275-280.
25. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004;79(12):1495-1500.
26. Morgenstern LB, Hemphill JC III, Anderson C, et al American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41(9):2108-2129.
27. Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial: Global Utilization of Streptokinase and Tissue-Plasminogen Activator (tPA) for Occluded Coronary Arteries. Am Heart J. 1999;138(3, pt 1):493-499.